Avacta
£12.5m raise completed, runway extended into Q227Avacta
H126: pre|CISION pipeline progress prompts fundraiseAvacta
Encouraging first data from AVA6103 Phase Ia studyAvacta
Tumour-activated drug delivery demonstratedAvacta
Raise of £9m pays down convertible bond to c £11.5mAvacta
FY25 results: clinical data will define the coming yearAvacta
AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trialAvacta
£10m raise extends runway beyond FAP-EXd catalystsAvacta
Innovative AI analysis comparing pre|CISION PDCs to ADCsAvacta
pre|CISION prospects build